                         SEQUENCE LISTING

<110>  Purdue Research Foundation
 
<120>  Compounds, Compositions and Methods of Use to Treat Bone 
       Fractures

<130>  69248-03

<150>  63/105,669
<151>  2020-10-26

<150>  63/193,748
<151>  2021-05-27

<160>  21    

<170>  PatentIn version 3.5

<210>  1
<211>  86
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  modified parathyroid hormone-related protein (PTHrP)

<400>  1

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln 
1               5                   10                  15      


Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His 
            20                  25                  30          


Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro Asn Ser Lys Pro 
        35                  40                  45              


Ser Pro Asn Thr Lys Asn His Pro Val Arg Phe Gly Ser Asp Asp Glu 
    50                  55                  60                  


Gly Arg Tyr Leu Thr Gln Glu Thr Asn Lys Val Glu Thr Tyr Lys Glu 
65                  70                  75                  80  


Gln Pro Leu Lys Thr Pro 
                85      


<210>  2
<211>  34
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  abaloparatide, an analog of PTHrP


<220>
<221>  SITE
<222>  (29)..(29)
<223>  Where "X" is alpha-aminoisobutyric acid

<220>
<221>  SITE
<222>  (29)..(29)
<223>  where "X" is alpha-aminoisobutyric acid

<400>  2

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln 
1               5                   10                  15      


Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Xaa Lys Leu His 
            20                  25                  30          


Thr Ala 
        


<210>  3
<211>  56
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a conjugate with 10 glutamic acid residues


<220>
<221>  SITE
<222>  (29)..(29)
<223>  where "X" is methylalanine

<400>  3

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln 
1               5                   10                  15      


Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Xaa Lys Leu His 
            20                  25                  30          


Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro Asn Ser Glu Glu 
        35                  40                  45              


Glu Glu Glu Glu Glu Glu Glu Glu 
    50                  55      


<210>  4
<211>  65
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a conjugate with 20 glutamic acid residues


<220>
<221>  SITE
<222>  (29)..(29)
<223>  where "X" is alpha-aminoisobutyric acid

<400>  4

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln 
1               5                   10                  15      


Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Xaa Lys Leu His 
            20                  25                  30          


Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro Asn Ser Glu Glu 
        35                  40                  45              


Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu 
    50                  55                  60                  


Glu 
65  


<210>  5
<211>  42
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a modified peptide hormone conjugate with 10 glutamic acid 
       residues


<220>
<221>  MISC_FEATURE
<222>  (11)..(12)

<400>  5

His Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Arg Gly Ala Ser Gln 
1               5                   10                  15      


Arg Trp Thr Asp Tyr Gln Phe Phe Gly Val Pro Tyr Arg Pro Phe Asp 
            20                  25                  30          


Pro Leu Val Ala Gln Ser Thr Ser Val Asp 
        35                  40          


<210>  6
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  D10-ester-dasatinib


<220>
<221>  SITE
<222>  (1)..(1)
<223>  where "X" indicates ester-dasatinib

<400>  6

Xaa Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp 
1               5                   10      


<210>  7
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a conjugate with 10 glutamic acid residues


<220>
<221>  MISC_FEATURE
<222>  (11)..(12)

<400>  7

His Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Arg Arg Glu Thr Ala 
1               5                   10                  15      


Trp Ala 
        


<210>  8
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  OTHER INFORMATION: ITGA conjugated with 10 glutamic acid residues
       (ITGA5)


<220>
<221>  MISC_FEATURE
<222>  (11)..(12)

<400>  8

His Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Arg Arg Glu Thr Ala 
1               5                   10                  15      


Trp Ala 
        


<210>  9
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a conjugate with 10 glutamic acid residues


<220>
<221>  MISC_FEATURE
<222>  (11)..(12)

<400>  9

His Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Lys Leu Thr Trp Gln 
1               5                   10                  15      


Glu Leu Tyr Gln Leu Lys Tyr Lys Gly Ile 
            20                  25      


<210>  10
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a conjugate with 10 aspartic acid residues


<220>
<221>  MISC_FEATURE
<222>  (11)..(12)

<400>  10

His Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Arg Pro Lys Pro Gln 
1               5                   10                  15      


Gln Phe Phe Gly Leu Met 
            20          


<210>  11
<211>  65
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a conjugate with 20 glutamic acid residues


<220>
<221>  misc_feature
<222>  (29)..(29)
<223>  Xaa can be any naturally occurring amino acid

<400>  11

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln 
1               5                   10                  15      


Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Xaa Lys Leu His 
            20                  25                  30          


Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro Asn Glu Glu Glu 
        35                  40                  45              


Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu 
    50                  55                  60                  


Glu 
65  


<210>  12
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a linker

<400>  12

Glu Ile Arg Ala Thr Ser Glu Val Ser Pro Asn Ser 
1               5                   10          


<210>  13
<211>  56
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a conjugate with 10 glutamic acid residues


<220>
<221>  SITE
<222>  (47)..(56)
<223>  where the glutamic acid residues at positions 47-56 have 
       D-chirality

<400>  13

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 
1               5                   10                  15      


Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 
            20                  25                  30          


Asn Phe Val Ala Leu Gly Ala Pro Leu Ala Pro Arg Asp Ala Glu Glu 
        35                  40                  45              


Glu Glu Glu Glu Glu Glu Glu Glu 
    50                  55      


<210>  14
<211>  56
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a conjugate with 10 glutamic acid residues


<220>
<221>  SITE
<222>  (29)..(29)
<223>  where "X" is methylalanine

<220>
<221>  SITE
<222>  (47)..(56)
<223>  where the glutamic acid residues at positions 47-56 have 
       L-chirality

<400>  14

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln 
1               5                   10                  15      


Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Xaa Lys Leu His 
            20                  25                  30          


Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro Asn Ser Glu Glu 
        35                  40                  45              


Glu Glu Glu Glu Glu Glu Glu Glu 
    50                  55      


<210>  15
<211>  46
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a compound having the X-Y portion of Formula (I)


<220>
<221>  SITE
<222>  (29)..(29)
<223>  where "X" is alpha-aminoisobutyric acid or mehtylalanine

<400>  15

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln 
1               5                   10                  15      


Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Xaa Lys Leu His 
            20                  25                  30          


Thr Ala Glu Ile Arg Ala Thr Ser Glu Val Ser Pro Asn Ser 
        35                  40                  45      


<210>  16
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heparin-binding domain of FGF2

<400>  16

Tyr Lys Arg Ser Arg Tyr Thr Cys 
1               5               


<210>  17
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pituitary adenylate cyclase-activating polypeptide

<400>  17

His Ser Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln 
1               5                   10                  15      


Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Lys 
            20                  25                  30          


Gln Arg Val Lys Asn Lys Cys 
        35                  


<210>  18
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  chemotactic cryptic peptide, derived from the CTX region of 
       collagen type III

<400>  18

Tyr Ile Ala Gly Val Gly Gly Glu Lys Ser Gly Gly Phe Tyr Cys 
1               5                   10                  15  


<210>  19
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  casein kinase 2 beta chain

<400>  19

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


Ile Pro Val Gly Glu Ser Leu Lys Asp Leu Ile Asp Gln Cys 
            20                  25                  30  


<210>  20
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  osteopontin-derived peptide

<400>  20

Asp Val Asp Val Pro Asp Gly Arg Gly Asp Ser Leu Ala Tyr Gly Cys 
1               5                   10                  15      


<210>  21
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  BMP-2 fragment

<400>  21

Lys Ile Pro Lys Ala Ser Ser Val Pro Thr Glu Leu Ser Ala Ile Ser 
1               5                   10                  15      


Thr Leu Tyr Leu Cys 
            20      


